Literature DB >> 11780301

Role of bronchoscopy in massive hemoptysis.

R Karmy-Jones1, J Cuschieri, E Vallières.   

Abstract

Airway hemorrhage is a potentially rapidly fatal condition. Death may occur within minutes from asphyxiation before control can be achieved. The primary prognostic factors are the rate of bleeding and the underlying cardiopulmonary status of the patient. Bronchoscopy is central in management, but the goals differ, depending on circumstances. In stable patients who have minimal hemoptysis, bronchoscopy can diagnose the cause specifically and be used as the primary treatment modality. In the setting of massive or life-threatening bleeding, bronchoscopy primarily is performed to maintain ventilation and to direct endobronchial blockade. Although flexible bronchoscopy is an acceptable mode initially, there should be no delay in performing rigid bronchoscopy when it becomes apparent that bleeding is too vigorous to permit [figure: see text] successful airway exploration with the smaller flexible instrument. Once isolation of bleeding has been achieved, the choice must be made between embolization, surgical resection, or both of these procedures.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11780301

Source DB:  PubMed          Journal:  Chest Surg Clin N Am        ISSN: 1052-3359


  3 in total

Review 1.  Diagnosis and management of hemoptysis.

Authors:  Anna Rita Larici; Paola Franchi; Mariaelena Occhipinti; Andrea Contegiacomo; Annemilia del Ciello; Lucio Calandriello; Maria Luigia Storto; Riccardo Marano; Lorenzo Bonomo
Journal:  Diagn Interv Radiol       Date:  2014 Jul-Aug       Impact factor: 2.630

Review 2.  A systematic approach to the management of massive hemoptysis.

Authors:  Christopher Radchenko; Abdul Hamid Alraiyes; Samira Shojaee
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

Review 3.  Diagnosis and management of lung infections.

Authors:  Dawn E Jaroszewski; Brandon J Webb; Kevin O Leslie
Journal:  Thorac Surg Clin       Date:  2012-08       Impact factor: 1.750

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.